TY - JOUR
T1 - Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma
T2 - a phase II study
AU - Veronesi, A.
AU - Bo, V. Dal
AU - Re, G. Lo
AU - Valentina, M. Della
AU - Tirelli, U.
AU - Merlo, A.
AU - Talamini, R.
AU - Francini, M.
AU - Monfardini, S.
PY - 1989/2
Y1 - 1989/2
N2 - From February 1984 to February 1987, 29 patients with advanced, hormone-resistant prostatic carcinoma were treated with mitomycin-C at a dose of 20 mg/m2 every 6 weeks (15 mg/m2 in patients >75 years old and in those who had undergone previous radiotherapy). In the 27 evaluable patients, there were no complete remissions (CR), 2 partial remissions (PR), 14 stabilizations (STAB), and 11 cases of progressive disease (PRO). Ten stabilized patients showed significant pain reduction. Toxicity was minimal. The actuarial median survival was 10.8 months. In this study, mitomycin C was not active in terms of CR+PR; however, a beneficial symptomatic effect was frequently observed.
AB - From February 1984 to February 1987, 29 patients with advanced, hormone-resistant prostatic carcinoma were treated with mitomycin-C at a dose of 20 mg/m2 every 6 weeks (15 mg/m2 in patients >75 years old and in those who had undergone previous radiotherapy). In the 27 evaluable patients, there were no complete remissions (CR), 2 partial remissions (PR), 14 stabilizations (STAB), and 11 cases of progressive disease (PRO). Ten stabilized patients showed significant pain reduction. Toxicity was minimal. The actuarial median survival was 10.8 months. In this study, mitomycin C was not active in terms of CR+PR; however, a beneficial symptomatic effect was frequently observed.
UR - http://www.scopus.com/inward/record.url?scp=0024264919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024264919&partnerID=8YFLogxK
U2 - 10.1007/BF00273528
DO - 10.1007/BF00273528
M3 - Article
C2 - 2491963
AN - SCOPUS:0024264919
VL - 23
SP - 115
EP - 116
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - 2
ER -